Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 1:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo - Losartan Clear all
Completed No phase listed Observational

Long Term Effects of Enalapril and Losartan on Genetic Heart Disease

NCT00001534
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Myocardial Ischemia
Interventions
Losartan
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 18, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

Study of Losartan in the Treatment of NAFLD in Children

NCT01913470
View directory record Official record
Conditions
NAFLD
Interventions
Losartan
Drug
Lead sponsor
Miriam Vos, MD
Other
Eligibility
11 Years to 19 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 18, 2026, 1:33 PM EDT
Completed Phase 3 Interventional Results available

Renoprotection in Early Diabetic Nephropathy in Pima Indians

NCT00340678
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Losartan, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2014
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Sep 18, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

Olmesartan Comparison to Losartan in Hypertensive Subjects

NCT00949884
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan medoxomil, Placebo, losartan potassium
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Mesa, Arizona • Phoenix, Arizona • Harbor City, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Sep 18, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

NCT00673790
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol with concomitant losartan or lisinopril, HCTZ with concomitant losartan or lisinopril, Placebo with concomitant losartan or lisinopril
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
88
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Sep 18, 2026, 1:33 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan

NCT05025956
View directory record Official record
Conditions
Femoroacetabular Impingement
Interventions
Fisetin, Placebo
Drug
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 18, 2026, 1:33 PM EDT
Recruiting Phase 1Phase 2 Interventional

Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan

NCT06108063
View directory record Official record
Conditions
Knee Arthroplasty, Total
Interventions
Losartan, Placebo - Losartan
Drug
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 18, 2026, 1:33 PM EDT
Completed Phase 4 Interventional

The Effects of Angiotensin II Receptor Blockade on Kidney Function and Scarring After Liver Transplant

NCT00275639
View directory record Official record
Conditions
Liver Transplant Recipients
Interventions
Cozaar
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Sep 18, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial

NCT02049307
View directory record Official record
Conditions
Inflammation, Fibrosis
Interventions
Losartan 100mg daily, Matching placebo
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
50 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
San Francisco, California • Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Sep 18, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Losartan in Preventing Progression of COPD

NCT00720226
View directory record Official record
Conditions
COPD, Emphysema, Chronic Bronchitis, Smoking
Interventions
Losartan, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 18, 2026, 1:33 PM EDT
Terminated Phase 2 Interventional Results available

Losartan and Inflammation in Cystic Fibrosis

NCT03206788
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Losartan, placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Miami, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 18, 2026, 1:33 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Losartan to Improve Hip Microfracture

NCT04212650
View directory record Official record
Conditions
Hip Osteoarthritis, Hip Impingement Syndrome, Cartilage Damage, Fibrosis
Interventions
Losartan, Placebo
Drug · Other
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 18, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Results available

Study of Cardiovascular Disease and Obstructive Sleep Apnea

NCT01637623
View directory record Official record
Conditions
Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events/Hour), Hypertension
Interventions
Losartan, Allopurinol, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Green Bay, Wisconsin • La Crosse, Wisconsin • Madison, Wisconsin + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Sep 18, 2026, 1:33 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV

NCT01852942
View directory record Official record
Conditions
HIV Infection, HIV Infections
Interventions
Losartan, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 18, 2026, 1:33 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly

NCT01384591
View directory record Official record
Conditions
Aging
Interventions
N-acetylcysteine, Losartan, Placebo losartan, Placebo N-acetylcysteine
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 18, 2026, 1:33 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Local Vasoconstriction in Postural Tachycardia Syndrome

NCT01210430
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Losartan, Ascorbic Acid (Vitamin C), Normal Saline
Drug
Lead sponsor
New York Medical College
Other
Eligibility
14 Years to 29 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 18, 2026, 1:33 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis

NCT00981747
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
Interventions
Sildenafil, Losartan, Sildenafil and Losartan, Placebo Oral Tablet
Drug
Lead sponsor
Alicia Gerke
Other
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 12, 2018 · Synced Sep 18, 2026, 1:33 PM EDT
Completed Phase 3 Interventional Results available

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

NCT00219141
View directory record Official record
Conditions
Hypertension, Left Ventricular Hypertrophy, Overweight
Interventions
Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Sep 18, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

Angiotensin II Blockade for Chronic Allograft Nephropathy

NCT00067990
View directory record Official record
Conditions
Kidney Disease, Proteinuria
Interventions
Losartan 100mg, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2017 · Synced Sep 18, 2026, 1:33 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

NCT02232880
View directory record Official record
Conditions
Hypertension
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 18, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

Losartan Effects on Emphysema Progression

NCT02696564
View directory record Official record
Conditions
Emphysema
Interventions
Losartan, Placebo
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
40 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
28
States / cities
Birmingham, Alabama • Tucson, Arizona • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Sep 18, 2026, 1:33 PM EDT
Recruiting Phase 2 Interventional

Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.

NCT06364176
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Losartan, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
12 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 18, 2026, 1:33 PM EDT
Active, not recruiting Phase 2 Interventional

Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

NCT05637216
View directory record Official record
Conditions
Radiation Induced Fibrosis
Interventions
Losartan 25 milligram capsule, Placebo
Drug
Lead sponsor
Shaw Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Edwards, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 18, 2026, 1:33 PM EDT
Completed Phase 4 Interventional Results available

A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients

NCT00675987
View directory record Official record
Conditions
Obesity, Hypertension, Hyperglycemia
Interventions
losartan, Placebo control
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Little Rock, Arkansas • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 18, 2026, 1:33 PM EDT